<i>Fmo1</i> Gene Expression Independently Predicts Favorable Recurrence-Free Survival of Classical Papillary Thyroid Cancer

Abstract

<b>Aim:</b> To examine the expression profile of <i>FMO1</i> in papillary thyroid cancer (PTC) and its prognostic value in recurrence-free survival (RFS). <b>Methods:</b> A retrospective analysis was performed using data from the Cancer Genome Atlas and Human Protein Atlas. <b>Results:</b> The most frequent variants of PTC had decreased <i>FMO1</i> expression compared with their respective adjacent normal tissues. However, even under the best cut-off model, high <i>FMO1</i> expression was only significantly associated with better RFS in classical PTC (p < 0.001), but not in other two variants. High <i>FMO1</i> expression independently predicted favorable RFS (hazard ratio: 0.202; 95% CI: 0.084-0.487; p < 0.001) in classical PTC. <b>Conclusion</b>: High <i>FMO1</i> expression might serve as a biomarker that independently predicts favorable RFS in classical PTC patients.